Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T van Laar

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Current Protein & Peptide Science|October 9, 2002
Mif1: a missing link between the unfolded protein response pathway and ER-associated protein degradation?T van Laar, A J van der Eb, C Terleth
Spinal Cord|April 1, 2009
The incidence and management of tolerance in intrathecal baclofen therapyH W Heetla, M J Staal, C Kliphuis, et al.
BMC Neurology|May 1, 2024
Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutationO Siemeling, S Slingerland, S van der Zee, et al.
Clinical Neuropharmacology|February 1, 1994
Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responsesD J Hofstee, C Neef, T van Laar, et al.
Archives of Neurology|May 1, 1992
Intranasal apomorphine in parkinsonian on-off fluctuationsT van Laar, E N Jansen, A W Essink, et al.
Psychiatry Research|August 26, 2019
Visual hallucinations in psychosisM M van Ommen, T van Laar, F W Cornelissen, et al.
Molecular Carcinogenesis|June 29, 2001
Induction of the SAPK activator MIG-6 by the alkylating agent methyl methanesulfonateT van Laar, T Schouten, A J van der Eb, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1995
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositoriesT van Laar, E N Jansen, C Neef, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1996
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's diseaseT van Laar, C Neef, M Danhof, et al.
Clinical Neuropharmacology|October 23, 1997
Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and thresholdJ J van Hilten, E A Wagemans, S F Ghafoerkhan, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Current Protein & Peptide Science|October 9, 2002
Mif1: a missing link between the unfolded protein response pathway and ER-associated protein degradation?T van Laar, A J van der Eb, C Terleth
Spinal Cord|April 1, 2009
The incidence and management of tolerance in intrathecal baclofen therapyH W Heetla, M J Staal, C Kliphuis, et al.
BMC Neurology|May 1, 2024
Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutationO Siemeling, S Slingerland, S van der Zee, et al.
Clinical Neuropharmacology|February 1, 1994
Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responsesD J Hofstee, C Neef, T van Laar, et al.
Archives of Neurology|May 1, 1992
Intranasal apomorphine in parkinsonian on-off fluctuationsT van Laar, E N Jansen, A W Essink, et al.
Psychiatry Research|August 26, 2019
Visual hallucinations in psychosisM M van Ommen, T van Laar, F W Cornelissen, et al.
Molecular Carcinogenesis|June 29, 2001
Induction of the SAPK activator MIG-6 by the alkylating agent methyl methanesulfonateT van Laar, T Schouten, A J van der Eb, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1995
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositoriesT van Laar, E N Jansen, C Neef, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1996
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's diseaseT van Laar, C Neef, M Danhof, et al.
Clinical Neuropharmacology|October 23, 1997
Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and thresholdJ J van Hilten, E A Wagemans, S F Ghafoerkhan, et al.
Pageof 7